Plus Therapeutics' REYOBIQ gets FDA Orphan Drug Designation for pediatric malignant gliomas

PLUS THERAPEUTICS, INC.

ODD covers pediatric malignant gliomas including ependymoma, broader than originally requested.
Designation provides 7 years of market exclusivity upon approval, tax credits, and fee exemptions.
Follows FDA Type B meeting supporting development in leptomeningeal metastases and IND clearance for pediatric high-grade glioma and ependymoma.
REYOBIQ delivers targeted radiotherapy to CNS tumors while minimizing healthy brain exposure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.